Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038311 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00038311 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT00038311, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of an investigational drug in the prevention of thrombocytopenia in patients with high-risk sarcoma receiving AI (Adriamycin/Ifosfamide) chemotherapy.
Interventions
- DRUG PN-152,243)/PN-196,444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2000-09 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038311
The ClinicalTrials.gov registry entry for NCT00038311 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PN-152,243)/PN-196,444 is the first listed.
NCT00038311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038311 about?
NCT00038311 is a clinical study titled "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia". Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of an investigational drug in the...
What is the current status of trial NCT00038311?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2000-09. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00038311?
The interventions under investigation include: PN-152,243)/PN-196,444 (DRUG).
Who is sponsoring clinical trial NCT00038311?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.